Wills Hughes-Wilson | Chief Patient Access & Commercial Planning
Mereo Biopharma

Wills Hughes-Wilson is Chief Patient Access & Commercial Planning at Mereo Biopharma and a member of the company’s executive leadership team.  She joined Mereo in March 2018 with responsibility for leading the company’s access and commercialisation strategies across the portfolio.   Prior to joining Mereo, Hughes-Wilson was Chief Patient Access Officer and SVP Patient Access & External Affairs at Sobi, with executive accountability for Sobi’s go-to-market approach across a broad orphan drug portfolio, including the company’s successful first-in-class haemophilia product launches; as well as market-oriented development across the company’s early-stage clinical development programmes.  Previous to that, she was Vice President Health & Market Access Policy at Genzyme.   Hughes-Wilson has been an active participant in the field of rare diseases and orphan drugs since the early 2000s, spanning membership of the EMA’s COMP Working Group with Interested Parties, the European Commission’s EU Committee of Experts on Rare Diseases (EUCERD) and, currently, the Steering Group of the European Mechanism of Coordinated Access (MoCA).   Hughes-Wilson is an honours graduate in Law & Politics.